- Home
- OPT vs TNYA Comparison
OPT vs TNYA Comparison
Compare OPT & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- TNYA
- Stock Information
- Founded
- OPT 1984
- TNYA 2016
- Country
- OPT Australia
- TNYA United States
- Employees
- OPT N/A
- TNYA N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- TNYA Medicinal Chemicals and Botanical Products
- Sector
- OPT Health Care
- TNYA Health Care
- Exchange
- OPT Nasdaq
- TNYA Nasdaq
- Market Cap
- OPT 201.5M
- TNYA 190.9M
- IPO Year
- OPT 2020
- TNYA 2021
- Fundamental
- Price
- OPT $3.24
- TNYA $1.98
- Analyst Decision
- OPT Strong Buy
- TNYA Strong Buy
- Analyst Count
- OPT 2
- TNYA 5
- Target Price
- OPT $14.00
- TNYA $15.25
- AVG Volume (30 Days)
- OPT 10.8K
- TNYA 387.1K
- Earning Date
- OPT 08-30-2024
- TNYA 08-08-2024
- Dividend Yield
- OPT N/A
- TNYA N/A
- EPS Growth
- OPT N/A
- TNYA N/A
- EPS
- OPT N/A
- TNYA N/A
- Revenue
- OPT $261,859.00
- TNYA N/A
- Revenue This Year
- OPT N/A
- TNYA N/A
- Revenue Next Year
- OPT $55,563.16
- TNYA $360.00
- P/E Ratio
- OPT N/A
- TNYA N/A
- Revenue Growth
- OPT N/A
- TNYA N/A
- 52 Week Low
- OPT $1.60
- TNYA $1.66
- 52 Week High
- OPT $4.40
- TNYA $7.01
- Technical
- Relative Strength Index (RSI)
- OPT 70.30
- TNYA 29.27
- Support Level
- OPT $2.84
- TNYA $1.95
- Resistance Level
- OPT $3.19
- TNYA $2.90
- Average True Range (ATR)
- OPT 0.14
- TNYA 0.21
- MACD
- OPT 0.01
- TNYA -0.04
- Stochastic Oscillator
- OPT 100.00
- TNYA 4.95
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.